(Press-News.org) Northridge, Calif. (October 16, 2014) – Post-menopausal women experienced improvements in vaginal atrophy, with no significant effect on hormone levels or genital bleeding, after 12 weeks of daily 10 milligram (mg) doses of an investigational fermented soy germ-based nutritional supplement previously shown to help relieve certain menopause symptoms, according to a new peer-reviewed pilot study reported in a poster at the North American Menopause Society (NAMS) annual scientific meeting.
"These data documented improved vaginal epithelium, without significant abnormalities in vaginal cells, endometrial thickening, hormone levels or genital bleeding, which adds to the known safety profile of this S-equol supplement," said coauthor Belinda H. Jenks, Ph.D., director of Scientific Affairs & Nutrition Education at Pharmavite LLC, the makers of Nature Made® vitamins and minerals and a subsidiary of Otsuka Pharmaceutical Co., Ltd., which supported the study.
In menopausal women, estrogen loss is the major cause of atrophy of the tissues of the reproductive and urinary systems, which usually is progressive (Calleja-Agius and Brincat, 2009) and includes vaginal dryness, itching, burning, dyspareunia (painful intercourse) and urinary incontinence. While estrogen replacement therapy can help manage these symptoms, some women do not use such hormone-based therapy because of side effect concerns (Uchiyama et al., 2014).
S-equol has the ability to bind to the same estrogen receptors as naturally occurring estrogen, with a stronger affinity to the beta receptor compared to the alpha receptor. On binding to the receptor, S-equol mimics some, but not all, activities of estrogen. Because of these actions at the receptor, it has been proposed that S-equol may alleviate some symptoms caused by diminished estrogen production during menopause. Daily doses of the supplement containing S-equol, a metabolite of the soy isoflavone daidzein, can relieve hot flash frequency and muscle and joint pain, as reported in previously published controlled clinical trials in both U.S. and Japanese postmenopausal women.
Vaginal and Reproductive Health Benefits
Daily 10 mg doses of S-equol for 12 weeks showed an improvement in vaginal epithelium in 105 post-menopausal Japanese women, who were not S-equol producers. The researchers used the percentage of superficial cells, to determine vaginal atrophy, as the disappearance of these cells is associated with dryness and increased risk of some conditions such as candida (yeast) infections, known to cause itch and inflammation.
Investigators examined three daily doses of S-equol, 2, 6 and 10 mg, and a placebo, with tissue evaluations at the study start and 12 weeks. Specifically, the 10 mg group showed a positive trend to superiority compared to the placebo group, respectively +6.3 vs. -4.4 percent change in superficial cells at 12 weeks, P=0.0507, while the 2 and 6 mg groups showed dose-related changes of -2.2 and +2.7 percent, (P=0.6350 and P=0.2011) respectively, which did not differ significantly from the placebo group. None of the groups displayed an increase in abnormal vaginal cells.
Likewise, the women's change in endometrial thickness after 12 weeks showed no significant differences between groups: 3.6±1.1 millimeter (mm) in the placebo group, 4.0±1.1 mm for the 2 mg group, 3.8±2.3 for the 6 mg group, and 4.6±2.4 mm for the 10 mg group. No treatment group showed significant genital bleeding. Additionally, no significant differences occurred in the groups based on measures of their blood levels of estrogen, follicle stimulating hormone, testosterone, thyroid-stimulating hormone, triiodothyronine (T3) and thyroxine (T4).
Complete data from the study will be submitted to a peer-review journal for publication.
INFORMATION:
About Equol
S-equol is a compound resulting from the natural metabolism, or conversion, of daidzein, an isoflavone found in whole soybeans. Not everyone can produce S-equol after soy consumption, as the production depends on the types of bacteria present in the large intestine. About 50 percent of Asians and 20 to 30 percent of North Americans and Europeans, who in general consume less soy than Asians, have the ability to produce equol.
The safety of the supplement containing S-equol previously was confirmed by standard animal testing breast cancer model, including a study documenting that S-equol itself, as well as the supplement containing S-equol, did not increase or stimulate the growth of breast cancer cells. Studies involving postmenopausal women who consumed the supplement containing S-equol have not observed any safety problems, including analysis of breast and reproductive tissues and of hormone levels.
Development and ongoing research of a supplement containing S-equol is conducted by the Saga Nutraceuticals Research Institute of Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd, along with Pharmavite LLC, a subsidiary of Otsuka, have and continue to study the supplement containing S-equol for the management of menopausal symptoms.
More information about S-equol, including results of studies, is at http://www.naturalequol.com.
How the S-equol Supplement is Made
The supplement is the product of fermentation of whole soy germ by the bacterial strain Lactococcus 20-92 using a patented and proprietary process by the Otsuka Pharmaceutical Co., Ltd. The process results in the conversion of the soy isoflavone daidzein to S-equol. The S-equol ingredient is created under current Good Manufacturing Practices. Following fermentation, the bacteria undergo heat denaturation and are deactivated. The process is designed to produce a S-equol rich product, or nutraceutical ingredient. The ingredient has self-affirmed GRAS (Generally Recognized As Safe) status.
NAMS Poster #P-107, October 16, 2014, 6:00 pm – 7:00 pm
A Pilot Study of S-equol Supplement (SE5-OH) on Reproductive Health in Postmenopausal Japanese Women
Shigeto Uchiyama, M.S., Tomomi Ueno, M.S., and Soh Iwashita, Ph.D., all of Saga Nutraceuticals Research Institute, Otsuka Pharmaceuticals Co., Ltd.,; Belinda H. Jenks, Ph.D., and James Brooks., Ph.D., both of Scientific Affairs of Pharmavite LLC; and Takeshi Aso, M.D., Ph.D., Professor and Chairman Emeritus, Department of Comprehensive Reproductive Medicine at the Tokyo Medical and Dental University and of Kyoundo Hospital in Tokyo, Japan. Iwashita also has an appointment with Scientific Affairs of Pharmavite LLC.
About Pharmavite LLC:
For more than 40 years, Pharmavite LLC has earned and maintained the trust of healthcare professionals, consumers, and retailers by manufacturing high-quality vitamins, minerals and other dietary supplements, and all-natural foods under its Nature Made® and SOYJOY® brand names. Based in Northridge, California, Pharmavite LLC operates as a subsidiary of Otsuka Pharmaceutical Co., Ltd. For more information, please visit Pharmavite.com.
About Otsuka Pharmaceutical Co., Ltd.:
Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group has business operations in 25 countries and regions around the world, with consolidated sales of approximately USD 14.1 billion for fiscal year 2013 (4/1/2013-3/31/2014.) Otsuka Pharmaceutical welcomes you to visit its global website at https://www.otsuka.co.jp/en
References:
Calleja-Agius J, Brincat MP. "Urogenital atrophy." Climacteric. 2009 Aug;12(4):279-85. doi: 10.1080/13697130902814751.
Uchiyama S, Ueno T, Iwashita S, Jenks BH, Brooks J, Aso T. A Pilot Study of S-equol Supplement (SE5-OH) on Reproductive Health in Postmenopausal Japanese Women, presented at North American Menopause Society 2014 Annual Meeting, October 16, 2014, Washington, D.C.
S-equol supplements associated with improved measures of reproductive health in postmenopausal women
2014-10-16
ELSE PRESS RELEASES FROM THIS DATE:
Curious signal hints at dark matter
2014-10-16
Space scientists at the University of Leicester have detected a curious signal in the X-ray sky – one that provides a tantalising insight into the nature of mysterious Dark Matter.
The Leicester team has found what appears to be a signature of 'axions', predicted 'Dark Matter' particle candidates – something that has been a puzzle to science for years.
In a study being published on Monday 20 October in the Monthly Notices of the Royal Astronomical Society, the University of Leicester scientists describe their finding of a signal which has no conventional ...
Executive scandal hurts job prospects even for entry-level employees
2014-10-16
October 16, 2014 – There's more bad news for job seekers with a scandal-hit company like Lehman Brothers or Countrywide Mortgage on their résumés. As if it weren't already hard enough to get a new job in this market, people who worked for one of those companies have tarnished reputations to overcome: New research finds that moral suspicion from higher-ups' wrongdoing spills down to people lower in an organization, even if they did not work directly under the moral transgressor.
"We became interested in the plight of people whose career trajectories were ...
Brain's compass relies on geometric relationships, say Penn Researchers
2014-10-16
VIDEO:
The brain has a complex system for keeping track of which direction you are facing as you move about; remembering how to get from one place to another would otherwise...
Click here for more information.
The brain has a complex system for keeping track of which direction you are facing as you move about; remembering how to get from one place to another would otherwise be impossible. Researchers from the University of Pennsylvania have now shown how the brain anchors this ...
How, when, and why industrial ecology is good for business
2014-10-16
Industrial ecology, a rapidly growing field focused on sustainable production and consumption, has contributed numerous important tools to modern environmental management — life cycle assessment; "industrial symbiosis," or the by-product exchange between neighboring facilities; "design for environment"; and the use of material flow analysis to track resource use in supply chains, companies, and economies.
A new special feature of Yale's Journal of Industrial Ecology, titled "Industrial Ecology as a Source of Competitive Advantage," presents new research on how, ...
Study shows inpatient palliative care reduces hospital costs and readmissions
2014-10-16
New Rochelle, NY, October 15, 2014—Palliative care provided in the hospital offers known clinical benefits, and a new study shows that inpatient palliative care can also significantly lower the cost of hospitalization and the rate of readmissions. Further, the study shows the hospital can get the expertise it needs through a collaborative relationship with a community hospice. The results of a comparative study are published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal ...
Novel RNAi-based therapy for anemia stimulates liver to produce EPO
2014-10-16
New Rochelle, NY, October 16, 2014—To treat the debilitating anemia associated with reduced erythropoietin (EPO) production by the kidneys in chronic renal disease, patients are often given recombinant human EPO to increase hemoglobin levels. But that treatment has risks. A new approach that uses a small interfering RNA (siRNA) drug to stimulate natural EPO production by the liver has shown promising results in nonhuman primates, as reported in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free ...
Public health in the 21st century
2014-10-16
Ann Arbor, MI, October 16, 2014 – Although disease outbreaks and epidemics drawing worldwide attention emphasize the importance and acute need for public health professionals, the world faces a longer-term challenge—a public health workforce that is truly effective in the 21st century. In a new supplement to the American Journal of Preventive Medicine, experts address critical challenges to public health, from workforce development, capacity building, partnership and collaborations, and changes and needs in workforce composition.
As the U.S. healthcare system ...
New test can help doctors choose best treatment for ovarian cancer
2014-10-16
Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment.
Successful treatment depends in part on accurately identifying the type of tumour, but this can be difficult. As a result, many women with cancer are not sent to the right specialist surgeon, or those with a benign cyst may have a more serious operation than they need.
In a study published today in the British Medical Journal, an international team led by Imperial College London and KU Leuven, Belgium describe a new test, called ADNEX, which can discriminate ...
Slow and steady does not win the weight loss race
2014-10-16
Led by Joseph Proietto, Sir Edward Dunlop Professor of Medicine at the University of Melbourne and Head of the Weight Control Clinic at Austin Health, the study also found that substantial weight loss is more likely to be achieved if undertaken rapidly.
"This randomised study highlights the urgent need for committees that develop clinical guidelines for the management of obesity to change their advice," he said.
The trial included 200 obese adults (BMI 30–45kg/m²) who were randomly assigned to either a 12-week rapid weight loss programme (average weight ...
Cryptic clues drive new theory of bowel cancer development
2014-10-16
Melbourne researchers have challenged conventional thinking on how the bowel lining develops and, in the process, suggested a new mechanism for how bowel cancer starts.
The researchers produced evidence that stem cells are responsible for maintaining and regenerating the 'crypts' that are a feature of the bowel lining, and believe these stem cells are involved in bowel cancer development, a controversial finding as scientists are still divided on the stem cells' existence.
Using 3D imaging technologies, Dr Chin Wee Tan and Professor Tony Burgess from the Walter and ...